Valuation: Arcus Biosciences, Inc.

Market Cap 3.76B 3.25B 3.05B 2.78B 5.22B 360B 5.3B 35.82B 14.04B 180B 14.11B 13.8B 600B P/E 2026 *
-8.25x
P/E 2027 * -8.19x
Enterprise Value 3.32B 2.86B 2.7B 2.45B 4.61B 318B 4.68B 31.62B 12.39B 159B 12.45B 12.18B 529B EV / Sales 2026 *
42.2x
EV / Sales 2027 * 70.2x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -
1 day-0.17%
1 week+2.68%
Current month+4.68%
1 month+7.82%
3 months+26.11%
6 months+51.88%
Current year+23.84%
1 week 27.97
Extreme 27.97
30.04
1 month 26.19
Extreme 26.19
31.09
Current year 18.52
Extreme 18.515
31.74
1 year 9.92
Extreme 9.92
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 30/04/2015
Chief Executive Officer 67 30/04/2015
Director of Finance/CFO 53 31/07/2020
Director TitleAgeSince
Chairman 67 30/11/2017
Director/Board Member 65 17/09/2017
Director/Board Member 72 30/04/2015
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Sell

Founder

-20,067 0.0160%
11/06/26 Free

Director

22,600 0.0180%
23/01/26 Free

Chief Financial Officer

157,000 0.1269%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+2.68%+181.85%+54.99% 3.76B
+1.36%+1.87%+2.96%+22.75% 48.63B
+1.89%+5.08%+492.59%+629.24% 46.3B
+1.83%+2.75%+15.61%+91.22% 41.97B
-0.50%-1.56%+24.67%+12.17% 39.51B
-2.74%-7.13%+18.72%+49.04% 31.75B
-1.14%-2.51%+27.52%+136.42% 16.48B
+0.59%-2.25% - - 16.34B
+0.03%+0.11%+2.77%+29.61% 14B
-2.60%-1.00%+77.85%+40.37% 13.33B
Average -0.48%-0.59%+93.84%+118.42% 27.21B
Weighted average by Cap. -0.27%-0.38%+107.10%+154.51%

Financials

2026 *2027 *
Net sales 78.61M 67.89M 63.88M 58.06M 109M 7.53B 111M 749M 294M 3.77B 295M 289M 12.55B 52.08M 44.98M 42.32M 38.46M 72.34M 4.99B 73.4M 496M 195M 2.5B 196M 191M 8.31B
Net income -451M -390M -366M -333M -626M -43.21B -636M -4.3B -1.68B -21.61B -1.69B -1.66B -71.99B -451M -390M -367M -333M -627M -43.24B -636M -4.3B -1.69B -21.63B -1.69B -1.66B -72.03B
Net Debt -441M -381M -358M -325M -612M -42.22B -621M -4.2B -1.65B -21.12B -1.65B -1.62B -70.33B -102M -88.24M -83.02M -75.45M -142M -9.79B -144M -974M -382M -4.9B -384M -375M -16.31B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
18/08/26 US$29.51 -0.17% 896,392
17/08/26 US$29.56 +0.27% 2,174,609
14/08/26 US$29.48 +2.15% 1,151,107
13/08/26 US$28.86 -0.35% 984,904
12/08/26 US$28.96 +0.77% 943,850
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
29.51USD
Average target price
38.33USD
Spread / Average Target
+29.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock